Magnetic Resonance Imaging in Metabolic Diseases
Launched by UNIVERSITY OF ULM · Nov 25, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how brain imaging, specifically using magnetic resonance imaging (MRI), can help us understand differences in the brains of people with metabolic diseases compared to healthy individuals. The researchers believe that these brain differences might change over time due to factors like body weight or the progression of the disease. By looking at how the brain's structure and function relate to overall body health, this study aims to uncover important information that could help improve treatment for metabolic diseases.
To participate in this study, you must be an adult aged 18 or older and able to give your written consent. You can either have a metabolic disease or be a healthy control without any metabolic conditions. Participants will undergo MRI scans and share their medical history during routine visits to track changes over time. It's important to note that certain medical conditions, such as severe neurological disorders or a history of brain surgery, may exclude you from joining. This research is taking place at Ulm University Hospital and is currently looking for volunteers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with metabolic diseases OR
- • healthy control participants without metabolic diseases
- • written consent
- Exclusion Criteria:
- • History of traumatic brain injuries
- • preterm birth (≤34th week of pregnancy) of the study participant
- • history of brain surgery
- • structural brain changes (e.g., tumors, congenital abnormalities, etc.)
- • neurological developmental disorders (e.g., autism spectrum disorders, learning disabilities, intellectual disability)
- • epilepsy,
- • drug addiction
- • other severe neurological or severe psychiatric disorders (e.g., schizophrenia
- • pregnancy
- • acute clinically relevant inflammatory diseases
- • acute systemic or local infections
- • severe or etiologically unclear diseases depending on the principle investigators judgement
- • pre-existing intellectual impairment
- • significant limitations in language comprehension
- • absence of written consent
- • general exclusion criteria for MRI imaging (e.g., pacemaker systems, neurostimulators, cochlear implants)
About University Of Ulm
The University of Ulm is a leading academic institution located in Germany, renowned for its commitment to cutting-edge research and innovation in the fields of medicine and health sciences. As a clinical trial sponsor, the university leverages its robust network of researchers and clinical experts to advance medical knowledge and improve patient outcomes. With a focus on interdisciplinary collaboration, the University of Ulm conducts comprehensive clinical studies that adhere to the highest ethical standards and regulatory guidelines. Through its research initiatives, the university aims to contribute significantly to the development of new therapies and treatment modalities, fostering a deeper understanding of various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ulm, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported